explore -WSS

explore

author：knowledge 2025-08-12 09:08:44 - browse：85

Sarepta - Cambridge -AP — Kristoffer Tripplaar/Sipa via AP

To hear Sarepta CEO Doug Ingram tell it, the results Monday afternoon from a large trial of its gene therapy for Duchenne muscular dystrophy marked a clear medical breakthrough. “A massive win,” he told investors, that could lead to its approval for all patients with the fatal muscle-wasting disease regardless of age.

And yet the rest of the Duchenne community was more cautious in its enthusiasm. The study — the most rigorous test to date of a technology 30 years in the making — had technically failed, as so many had before it.

“It’s extremely frustrating,” said John Brandsema, a pediatric neurologist at Children’s Hospital of Philadelphia who worked on the study. “When you spend decades trying to bring therapies into the clinic for something so severe and just keep missing over and over again.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Chamber of Commerce, DOJ clash in court over drug prices

WSS

Congenital heart disease patients face new threat of heart failure

Midwives could help bridge maternal health disparities in the U.S.

Congenital heart disease patients face new threat of heart failure

Spinal cord stimulation reduces pain in amputees, study finds

Medicare to pay more for cardiac rehab in hospital outpatient clinics

Chamber of Commerce, DOJ clash in court over drug prices

focus

explore

knowledge

Medical records are filled with copy

How the messy conversation about Dolly changed bioethics

Hepatitis C has a cure — but many Americans still lack access to it

What PEPFAR has meant on the ground in Ukraine

Drug repurposing or repositioning? The language matters

Assistant physicians can help address the primary care shortage

Jerome Adams on the need for new antivirals for Covid

Chamber of Commerce, DOJ clash in court over drug prices

Apple is now the first public company to be valued at $3 trillion

Fed up with FDA, ALS advocates consider a take

focus

Grad students accuse University of California of wage theft

FDA panel to weigh safety of artificial wombs for preterm births

Grad students accuse University of California of wage theft

Why the quest to eradicate polio has stumbled

AI models in health care face new federal disclosure requirements

White House Covid adviser calls on docs to combat misinformation

explore

hotspot

entertainment

Wikipedia